[1] NMPA. Circular on the Publication of the Guiding Principles on Real World Evidence to Support Drug Development and Review (Trial)[EB/OL].(2020-01-07)[2023-06-18]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200107151901190.html. [2] JIANG X, LIU LR, ZHU H, et al.Enlightenment of foreign drug management systems on the drug management of the elderly in China[J].Herald of Medicine(医药导报), 2020, 39(8): 1166-1169. [3] SHU T, CHEN WG, HOU YF, et al.Research and application of the sentinel hospital pharmacovigilance system based on HIS[J].China Pharmacy(中国药房), 2017, 28(25): 3468-3471. [4] HOU YF, SONG HB, LIU HL, et al.Practice and discussion on active surveillance by China hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 212-214. [5] WANG LL, YANG Y, WANG SL.Application of the US FDA sentinel system and enlightenmen[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 81-87. [6] LIU HL, ZHENG MJ, LI XL, et al.Overview of implementation of E2B (R3) guidelines by ICH founding regulatory members[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 594-596. [7] NMPA. Regional Implementation Guide for Individual Case Safety Reporting E2B(R3).[EB/OL].(2019-11-22)[2023-06-18]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjzh/20191122091301498.html. [8] HOU YF, DONG D, XIONG WY, et al.Developement of ICSR E2B Guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 144-146. [9] ZHANG RX, LIU QY, WANG HL, et al.Practice of a pharmacist-delivered service model and situation of drug-related problems among chronic elderly patients with polypharmacy in our hospital[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(7): 630-634. [10] National Key Research and Development Program (2018YFC2002400) Subject Groups. Expert consensus on safety management of multi-drug administration in elderly patients with co-morbidities in the elderly[J]. Chinese Journal of Health Care and Medicine(中华保健医学杂志), 2021, 23(5): 548-554. [11] LI XY.Discussion on management mode of older adults with multimorbidity[J].Chinese Journal of Geriatric Heart Brain and Vessel Diseases(中华老年心脑血管病杂志), 2022, 24(5): 449-452. [12] TANG YC, GU PY JIN S, et al. Clinical observation of polypharmacy in the elderly aged over 80 years[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2018, 21(2): 156-159. [13] National Health and Health Commission of the People's Republic of China. Health Industry Standard of the People's Republic of China(中华人民共和国卫生行业标准)[S/OL]. (2023-03-07)[2023-08-10]. http://www.nhc.gov.cn/cms-search/downFiles/864c23896af04e9fbaaa45a36751ab1c.pdf. |